Dhami, Prabhjot
Moreno, Sylvain
Croarkin, Paul E. http://orcid.org/0000-0001-6843-6503
Blumberger, Daniel M.
Daskalakis, Zafiris J.
Farzan, Faranak
Clinical trials referenced in this document:
Documents that mention this clinical trial
Baseline markers of cortical excitation and inhibition predict response to theta burst stimulation treatment for youth depression
https://doi.org/10.1038/s41598-023-45107-1
Documents that mention this clinical trial
Baseline markers of cortical excitation and inhibition predict response to theta burst stimulation treatment for youth depression
https://doi.org/10.1038/s41598-023-45107-1
Article History
Received: 13 September 2022
Accepted: 16 October 2023
First Online: 4 November 2023
Competing interests
: P.E.C. has received research grant support from Pfizer, Inc., Neosync, Inc., and Neuronetics, Inc. He has received equipment support from Neuronetics, Inc. and MagVenture, Inc. for investigator-initiated studies. P.E.C. has served as a consultant for Procter & Gamble Company, Myriad Neuroscience, Sunovion, and Engrail Therapeutics. D.M.B. has received in-kind equipment support for investigator-initiated studies from Magventure, he has received research support and in-kind equipment support for an investigator-initiated study from Brainsway and is the site principal investigator for three sponsor-initiated studies for Brainsway; he has received medication supplies for an investigator-initiated trial from Indivior; and he has participated on an advisory board for Janssen. Z.J.D. has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc. and Magventure Inc. P.D., S.M. and F.F. report no biomedical financial interests or potential conflicts of interest.